GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (WBO:UCB) » Definitions » Other Current Payables

UCB (WBO:UCB) Other Current Payables : €1,023 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is UCB Other Current Payables?

UCB's Other Current Payables for the quarter that ended in Dec. 2023 was €1,023 Mil.

UCB's quarterly Other Current Payables declined from Dec. 2022 (€1,165 Mil) to Jun. 2023 (€0 Mil) but then increased from Jun. 2023 (€0 Mil) to Dec. 2023 (€1,023 Mil).

UCB's annual Other Current Payables increased from Dec. 2021 (€1,084 Mil) to Dec. 2022 (€1,165 Mil) but then declined from Dec. 2022 (€1,165 Mil) to Dec. 2023 (€1,023 Mil).


UCB Other Current Payables Historical Data

The historical data trend for UCB's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Other Current Payables Chart

UCB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 876.00 894.00 1,084.00 1,165.00 1,023.00

UCB Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,084.00 - 1,165.00 - 1,023.00

UCB Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.


UCB Other Current Payables Related Terms

Thank you for viewing the detailed overview of UCB's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.


UCB (WBO:UCB) Business Description

Industry
Address
Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

UCB (WBO:UCB) Headlines

No Headlines